A retrospective study on IVF/ICSI outcome in patients with anti-nuclear antibodies: the effects of prednisone plus low-dose aspirin adjuvant treatment

Anti-nuclear antibodies (ANA) are suspected of having relevance to adverse reproductive events. This study aims to investigate the potential effect of ANA on IVF/ICSI outcome and the therapeutic role of prednisone plus low-dose aspirin (P + A) adjuvant treatment in ANA + patients. The first IVF/ICSI...

Full description

Saved in:
Bibliographic Details
Published in:Reproductive biology and endocrinology 2013-10, Vol.11 (1), p.98-98, Article 98
Main Authors: Zhu, Qing, Wu, Li, Xu, Bo, Hu, Mei-Hong, Tong, Xian-Hong, Ji, Jing-Juan, Liu, Yu-Sheng
Format: Article
Language:English
Subjects:
Abortion, Spontaneous
Adult
Analysis
Antibodies
Antibodies, Antinuclear - blood
Artificial insemination
Aspirin
Aspirin - administration & dosage
Aspirin - therapeutic use
Autoimmune diseases
Complications and side effects
Female
Fertilization in Vitro
Humans
Medical research
Physiological aspects
Prednisone
Prednisone - therapeutic use
Pregnancy
Pregnancy Outcome
Psychological aspects
Retrospective Studies
Sexually transmitted diseases
STD
Steroids
Studies
Viral antibodies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anti-nuclear antibodies (ANA) are suspected of having relevance to adverse reproductive events. This study aims to investigate the potential effect of ANA on IVF/ICSI outcome and the therapeutic role of prednisone plus low-dose aspirin (P + A) adjuvant treatment in ANA + patients. The first IVF/ICSI cycles without P + A of sixty-six ANA + women were enrolled as the ANA + group, and the 233 first IVF/ICSI cycles of matched ANA- women served as the ANA- group. The ANA + group was divided into the Titre  1:320 subgroup. Twenty-one ANA + women with adverse outcomes in their first cycles (ANA + cycles without P + A) received P + A adjuvant treatment for three months before the second IVF/ICSI cycle (ANA + cycles with P + A). The clinical characteristics and the IVF/ICSI outcomes were compared, respectively, between 1) the ANA + group and the ANA- group, 2) the Titre  1:320 subgroup, and 3) the ANA + cycles without P + A and the ANA + cycles with P + A. No significant differences were observed between each of the two-group pairs in the clinical characteristics. The ANA + group exhibited significantly lower MII oocytes rate, normal fertilisation, pregnancy and implantation rates, as well as remarkably higher abnormal fertilisation and early miscarriage rates. The Titre 
ISSN:1477-7827
1477-7827
DOI:10.1186/1477-7827-11-98